Hayatine inhibits amino acid-induced mTORC1 activation as a novel mTOR-Rag A/C interaction disruptor
- 1 December 2021
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 583, 71-78
- https://doi.org/10.1016/j.bbrc.2021.10.014
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31701239, 31771573, 81602413, 81874198, 82073086)
This publication has 27 references indexed in Scilit:
- Clinical experience with temsirolimus in the treatment of advanced renal cell carcinomaTherapeutic Advances in Urology, 2015
- ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimersBioinformatics, 2014
- Rapalogs and mTOR inhibitors as anti-aging therapeuticsJCI Insight, 2013
- mTOR Inhibitors in Tuberous Sclerosis ComplexCurrent Neuropharmacology, 2012
- [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancersBioorganic & Medicinal Chemistry Letters, 2012
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor ActivityMolecular Cancer Therapeutics, 2011
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from RapamycinMolecular Cancer Therapeutics, 2011
- mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivoCancer Letters, 2010
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1Science, 2008
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006